IRF6 and breast cancer: We show here that ErbB2-dependent IRF6 downregulation reduces cellular levels of the pro-apoptotic protein BLNK [15] and that BLNK loss blocks anoikis of breast cancer cells and promotes their tumorigenicity in vivo.